Mike Piazza is probably gonna get boned in the Hall of Fame voting this year

46 Comments

Bill Shaikin has a column up today in which one of Roger Clemens’ lawyers argues for Clemens’ induction to the Hall of Fame. Shocker, I know. But apart from him, this passage piques my interest:

Clemens is one of the headline attractions in what could be the most divisive election in Hall of Fame history. The first-time candidates include Clemens, Barry Bonds, Mike Piazza and Sammy Sosa, each of whom has been linked to performance-enhancing substances.

Clemens, Bonds and Sosa’s PED resumes are pretty well-known, but Piazza has not been publicly cast into their league. The relevant data points:

  • He admitted in 2002 to using androstenedione early in his career, but andro was not banned in baseball until 2004;
  • Murray Chass has gone on an unhinged one-man crusade (see here, here, here and here), saying that since he saw that Piazza had acne on his back, he had to be a ‘roider.

That’s it. That’s the alpha and omega of Piazza being “linked” to PEDs.

I don’t know if Piazza did anything besides andro. Maybe he did. Lots of star players of his generation did. Maybe that autobiography of his that comes out next February will say so. Maybe someone with actual first-hand knowledge of it will lay the evidence out for us.

But as Hall of Fame voters sit here today, all they have is legal andro use and Murray Chass’ back acne, which has been discredited by dermatologists as any sort of dispositive evidence. I have this feeling that alone is going to be enough for a huge number of Hall of Fame voters to withhold their vote for Piazza, despite him being ridiculously, over-the-top qualified for first ballot induction.

Padres may have more interest in Dallas Keuchel than Bryce Harper

Dallas Keuchel
Getty Images
1 Comment

An interesting tidbit today from The Athletic’s Ken Rosenthal, who noted that ongoing talks between agent Scott Boras and the Padres have focused more on starting pitcher Dallas Keuchel than slugger Bryce Harper. Earlier this week, there were conflicting reports on the Padres’ level of interest in Harper — MLB Network’s Jon Heyman heard the club had not ruled out another big signing after getting Manny Machado, while Kevin Acee of the San Diego Union-Tribune talked to multiple sources who believed otherwise — but any agreement between the two is looking unlikelier by the day.

As for Keuchel, Rosenthal cautions that a potential deal is still a “longshot,” especially as the team has other, cheaper options in mind. The 31-year-old southpaw turned down a qualifying offer from the Astros last year and is likely angling for something north of the five-year, $90 million contract extension he rejected from the club in 2016. He’s coming off of another solid performance in Houston, where he went 12-11 in 34 starts with a 3.74 ERA, 2.6 BB/9, 6.7 SO/9, and 3.6 fWAR through 204 2/3 innings in 2018.

While Keuchel has failed to garner substantial interest around the league this offseason, Heyman points out that the Phillies are looking to establish themselves as frontrunners for the lefty — and they’re far less likely to have hang-ups about his asking price, too.